Skip to main content

Posts tagged with "Drug Development"

  • Drug Development

    The Brute Force Bias

    I wanted to return to that Nature Reviews Drug Discovery article I blogged about the other day. There’s one reason the authors advance for our problems that I thought was particularly well stated: what they call the “basic research/brute force” bias. The ‘basic research–brute force’ bias is the tendency to overestimate the a… Read More
  • Drug Assays

    Drug Discovery for Physicists

    There’s a good post over at the Curious Wavefunction on the differences between drug discovery and the more rigorous sciences. I particularly liked this line: The goal of many physicists was, and still is, to find three laws that account for at least 99% of the universe. But the situation in drug discovery is more… Read More
  • Drug Development

    Scaling Up a Strange Dinitro Compound (And Others)

    I wrote here about a very unusual dinitro compound that’s in the clinic in oncology. Now there’s a synthetic chemistry follow-up, in the form of a paper in Organic Process R&D. It’s safe to say that most process and scale-up chemists are never going to have to worry about making a gem-dinitroazetidine – or, for… Read More
  • Business and Markets

    The Terrifying Cost of a New Drug

    Matthew Herper at Forbes has a very interesting column, building on some data from Bernard Munos (whose work on drug development will be familiar to readers of this blog). What he and his colleague Scott DeCarlo have done is conceptually simple: they’ve gone back over the last 15 years of financial statements from a bunch… Read More
  • Drug Development

    Putting a Number on Chemical Beauty

    There’s a new paper out in Nature Chemistry called “Quantifying the Chemical Beauty of Drugs”. The authors are proposing a new “desirability score” for chemical structures in drug discovery, one that’s an amalgam of physical and structural scores. To their credit, they didn’t decide up front which of these… Read More
  • Biological News

    Fun With Epigenetics

    If you’ve been looking around the literature over the last couple of years, you’ll have seen an awful lot of excitement about epigenetic mechanisms. (Here’s a whole book on that very subject, for the hard core). Just do a Google search with “epigenetic” and “drug discovery” in it, any combination you like,… Read More
  • Drug Development

    Biogen: A “Decimated” Pipeline?

    You don’t want coverage like this: “Biogen CEO Tries to Refill Early-Stage Pipeline He Decimated”. That would be George Scanos: . . .Scangos and his research chief eliminated about 17 early-stage drug projects in 2010 and last year to hone the company’s focus, leaving it with only about four early-stage compounds. Biogen exi… Read More
  • Business and Markets

    Welcome To the Jungle! Here’s Your Panther.

    English has no word of its own for schadenfreude, so we’ve had to appropriate the German one, and we’re in the process of making it our own – just as we did with “kindergarten”, not to mention “ketchup” and “pyjamas”, among fifty zillion more. That’s because the emotion is not peculiar to… Read More
  • Drug Assays

    Do We Believe These Things, Or Not?

    Some of the discussions that come up here around clinical attrition rates and compound properties prompts me to see how much we can agree on. So, are these propositions controversial, or not? 1. Too many drugs fail in clinical trials. We are having a great deal of trouble going on with these failure rates, given… Read More
  • Chemical News

    Lead-Oriented Synthesis – What Might That Be?

    A new paper in Angewandte Chemie tries to open another front in relations between academic and drug industry chemists. It’s from several authors at GSK-Stevenage, and it proposes something they’re calling “Lead-Oriented Synthesis”. So what’s that? Well, the paper itself starts out as a quick tutorial on the state and p… Read More